Expedition Therapeutics

Recent Finacing

Series A

Recent Raise

$165M

Expedition Therapeutics is a biotech developing a once-daily, oral DPP1 inhibitor (EXPD-101) to treat COPD and other neutrophil-driven inflammatory diseases.

California, United States

1-10

Private

expeditiontx.com

Highlights

Focus Areas

Biotechnology

Recent Investors

D

Financials

$165M

Total Raised

1

Funding round

10

Investors

Team

Upgrade to view the team

See the team members at Expedition Therapeutics.